Maximizing liposome tumor delivery by hybridizing with tumor-derived extracellular vesicles
- PMID: 39171636
- PMCID: PMC11401241
- DOI: 10.1039/d4nr02191f
Maximizing liposome tumor delivery by hybridizing with tumor-derived extracellular vesicles
Abstract
Extracellular vesicles (EVs) have gained widespread interest due to their potential in the diagnosis and treatment of inflammation, autoimmune diseases, and cancers. EVs are lipidic vesicles comprising vesicles of endosomal origin called exosomes, microvesicles from membrane shedding, and apoptotic bodies from programmed cell death membrane blebbing that carry complex sets of cargo from their cells of origin, including proteins, lipids, mRNA, and DNA. EVs are rich in integrin proteins that facilitate intrinsic cellular communication to deliver their cargo contents and can also be used as biomarkers to study respective cellular conditions. Within this background, we hypothesized that when these EVs are hybridized with synthetic liposomes, it would help navigate the hybrid construct in the complex biological environment to find its target. Toward this endeavor, we have hybridized a synthetic liposome with EVs (herein called LEVs) derived from mouse breast cancer (4T1 tumors) cells and incorporated a rhodamine-B/near-infrared fluorescent dye to investigate their potential for cellular targeting and tumor delivery. Using membrane extrusion, we have successfully hybridized both entities resulting in the formation of LEVs and characterized their colloidal properties and stability over a period. While EVs are broadly dispersed nano- and micron-sized vesicles, LEVs are engineered as monodispersed with an average hydrodynamic size of 140 ± 5. Using immunoblotting and ELISA, we monitored and quantified the EV-specific protein CD63 and other characteristic proteins such as CD9 and CD81, which were taken as a handle to ensure the reproducibility of EVs and thus LEVs. These LEVs were further challenged with mice bearing orthotopic 4T1 breast tumors and the LEV uptake was found to be maximum in tumors and organs like the liver, spleen, and lungs when compared to control PEGylated liposomes in live animal imaging. Likewise, the constructs were capable of finding lung metastasis as observed in ex vivo imaging. We anticipate that this study can open avenues for drug delivery solutions that are superior in target recognition.
Similar articles
-
Macrophage-derived exosome-mimetic hybrid vesicles for tumor targeted drug delivery.Acta Biomater. 2019 Aug;94:482-494. doi: 10.1016/j.actbio.2019.05.054. Epub 2019 May 24. Acta Biomater. 2019. PMID: 31129363
-
Comparative proteomic analysis of three major extracellular vesicle classes secreted from human primary and metastatic colorectal cancer cells: Exosomes, microparticles, and shed midbody remnants.Proteomics. 2024 Jun;24(11):e2300057. doi: 10.1002/pmic.202300057. Epub 2023 Jul 28. Proteomics. 2024. PMID: 37507836
-
Acidic Conditions Promote Clustering of Cancer Cell Derived Extracellular Vesicles and Enhance their Fusion with Synthetic Liposomes.Langmuir. 2025 Feb 25;41(7):4533-4544. doi: 10.1021/acs.langmuir.4c04297. Epub 2025 Feb 12. Langmuir. 2025. PMID: 39943777
-
Extracellular vesicles for drug delivery.Adv Drug Deliv Rev. 2016 Nov 15;106(Pt A):148-156. doi: 10.1016/j.addr.2016.02.006. Epub 2016 Feb 27. Adv Drug Deliv Rev. 2016. PMID: 26928656 Review.
-
Extracellular vesicles as drug delivery systems: lessons from the liposome field.J Control Release. 2014 Dec 10;195:72-85. doi: 10.1016/j.jconrel.2014.07.049. Epub 2014 Aug 2. J Control Release. 2014. PMID: 25094032 Review.
Cited by
-
Extracellular Vesicle-Based Drug Delivery Systems in Cancer Therapy.Int J Mol Sci. 2025 May 19;26(10):4835. doi: 10.3390/ijms26104835. Int J Mol Sci. 2025. PMID: 40429976 Free PMC article. Review.
-
Emerging Biomimetic Drug Delivery Nanoparticles Inspired by Extracellular Vesicles.Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2025 Jul-Aug;17(4):e70025. doi: 10.1002/wnan.70025. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2025. PMID: 40840553 Free PMC article. Review.
References
-
- Yáñez-Mó M, Siljander PR-M, Andreu Z, Bedina Zavec A, Borràs FE, Buzas EI, Buzas K, Casal E, Cappello F, Carvalho J, Colás E, Cordeiro-da Silva A, Fais S, Falcon-Perez JM, Ghobrial IM, Giebel B, Gimona M, Graner M, Gursel I, Gursel M, Heegaard NHH, Hendrix A, Kierulf P, Kokubun K, Kosanovic M, Kralj-Iglic V, Krämer-Albers E-M, Laitinen S, Lässer C, Lener T, Ligeti E, Linē A, Lipps G, Llorente A, Lötvall J, Manček-Keber M, Marcilla A, Mittelbrunn M, Nazarenko I, Nolte-’t Hoen ENM, Nyman TA, O’Driscoll L, Olivan M, Oliveira C, Pállinger É, del Portillo HA, Reventós J, Rigau M, Rohde E, Sammar M, Sánchez-Madrid F, Santarém N, Schallmoser K, Stampe Ostenfeld M, Stoorvogel W, Stukelj R, Van der Grein SG, Helena Vasconcelos M, Wauben MHM and De Wever O, Journal of Extracellular Vesicles, 2015, 4, 27066. - PMC - PubMed
-
- Bebelman MP, Smit MJ, Pegtel DM and Baglio SR, Pharmacology & Therapeutics, 2018, 188, 1–11. - PubMed
-
- Rayamajhi S, Nguyen TDT, Marasini R and Aryal S, Acta biomaterialia, 2019, 94, 482–494. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous